Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enbrel for Uveitis in Juvenile Rheumatoid Arthritis
NCT00012506Phase 3Unknown
- Sponsor
- National Eye Institute
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in uveitis comparing Etanercept with Placebo (2 arms). Primary endpoints: Reduction of Anterior Chamber Cells at 4 months and Reduction in Anti-inflammatory Medications at 4 months. Status: unknown.
02
Drugs
etanercept
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT00012506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00012506.